CJC-1295 (CJC)

Growth Hormone Clinical trials

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of human GHRH with modifications to extend its half-life. The peptide stimulates growth hormone (GH) release from the pituitary gland in a pulsatile manner that mimics natural GH secretion. CJC-1295 exists in two forms: with and without Drug Affinity Complex (DAC). The DAC modification allows the peptide to bind to albumin in the bloodstream, dramatically extending its half-life from minutes to approximately 8 days. This makes CJC-1295 with DAC suitable for once-weekly administration while maintaining elevated GH and IGF-1 levels.

Key Data

Research Status
Clinical trials
Half-Life
8 days (with DAC), 30 min (without DAC)
Administration
Subcutaneous injection
Typical Dosage
100-200 mcg
Molecular Weight
3,367.9 Da (without DAC)
Molecular Formula
C152H252N44O42

Mechanism of Action

GHRH receptor agonist that stimulates pituitary to release GH in a pulsatile manner.

Reported Benefits

All information is presented for Research Use Only (RUO). Not medical advice.

← All Peptides Dosing Calculator Community Forum Home